PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.

Abstract

BACKGROUND:

A sequential combination of radiochemotherapy/endocrinotherapy and cytokine-induced killer cell (CIK) infusion has been shown to be an effective therapy for post-mastectomy breast cancer based on statistical analysis of the patient population. However, whether an individual could obtain an improved prognosis from CIK cell-based treatment remains unknown. In the present study, we focused on immune microenvironment regulation and specifically investigated the relationship between PD-L1 expression and survival benefit from CIK immunotherapy in breast cancer.

METHODS:

A total of 310 postoperative breast cancer patients who received comprehensive treatment were enrolled in this retrospective study, including 160 patients in the control group (received chemotherapy/radiotherapy/endocrinotherapy) and 150 patients in the CIK cell treatment group (received chemotherapy/radiotherapy/ endocrinotherapy and subsequent CIK infusion).

RESULTS:

We found that overall survival (OS) and recurrence-free survival (RFS) were significantly better in the CIK group than that in the control group. PD-L1 expression in tumor tissue sections was showed to be an independent prognostic factor for patients in the CIK treatment group using multivariate survival analysis. Further survival analysis in the CIK group showed that patients with PD-L1 tumor expression exhibited longer OS and RFS. In addition, among all patients who were enrolled in this study, only the patients with PD-L1 expression experienced survival benefits from CIK treatment.

CONCLUSIONS:

Our study showed the relationship between PD-L1 expression and CIK therapy and revealed that PD-L1 expression in the tumor is as an indicator of adjuvant CIK therapy for postoperative breast cancer.

• Authors: Zi-Qi Zhou, Jing-Jing Zhao, Qiu-Zhong Pan, Chang-Long Chen, Yuan Liu, Yan Tang, Qian Zhu, De-Sheng Weng, Jian-Chuan Xia
• Journal: Journal for immunotherapy of cancer (J Immunother Cancer) Vol. 7 Issue 1 Pg. 228 (08 27 2019) ISSN: 2051-1426 [Electronic] England
• PMID: 31455411 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Hormonal
• B7-H1 Antigen
• Biomarkers, Tumor
• CD274 protein, human

Topics

• Antineoplastic Agents, Hormonal (therapeutic use)
• B7-H1 Antigen (metabolism)
• Biomarkers, Tumor (metabolism)
• Breast Neoplasms (immunology, metabolism, mortality, therapy)
• Case-Control Studies
• Chemoradiotherapy (mortality)
• Combined Modality Therapy
• Cytokine-Induced Killer Cells (immunology, transplantation)
• Female
• Follow-Up Studies
• Gene Expression Regulation, Neoplastic
• Humans
• Immunotherapy (mortality)
• Infusions, Intravenous
• Middle Aged
• Postoperative Care
• Prognosis
• Retrospective Studies
• Survival Rate